Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jul;6(4):204-18.
doi: 10.1177/2040622315584113.

P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use

Nicholas B Norgard  1 , James J DiNicolantonio  2
Affiliations
Review

P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use

Nicholas B Norgard et al. Ther Adv Chronic Dis. 2015 Jul.

Abstract

Dual antiplatelet therapy (DAPT), which includes the combination of aspirin and a P2Y12 platelet receptor inhibitor, is a well-established antiplatelet regimen in the treatment of patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS). Three P2Y12 inhibitor options (clopidogrel, prasugrel and ticagrelor) are currently available, all having different efficacy and safety profiles along with contrasting contraindications, special warnings and precautions for use. This review compares and contrasts the unique P2Y12 antagonists in the NSTE-ACS setting, covering the latest evidence and their optimal use.

Keywords: P2Y12 antagonists; acute coronary syndrome; clopidogrel; prasugrel; ticagrelor.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare no conflicts of interest in preparing this article.

Similar articles

See all similar articles

Cited by

References

    1. Aleil B., Jacquemin L., De Poli F., Zaehringer M., Collet J., Montalescot G., et al. (2008) Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. JACC Cardiovasc Interv 1: 631–638. - PubMed
    1. Alexopoulos D. (2012) Prasugrel resistance: fact or fiction. Platelets 23: 83–90. - PubMed
    1. Alexopoulos D., Galati A., Xanthopoulou I., Mavronasiou E., Kassimis G., Theodoropoulos K., et al. (2012) Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol 60: 193–199. - PubMed
    1. Amsterdam E., Wenger N., Brindis R., Casey D., Jr., Ganiats T., Holmes D., Jr., et al. (2014) 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 64: e139–e228. - PubMed
    1. Angiolillo D. (2009) Variability in responsiveness to oral antiplatelet therapy. AJC 103: 27–34. - PubMed

LinkOut - more resources